A decrease in fluorodeoxyglucose uptake by NSCLC tumors treated with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), identified more patients who responded to treatment than conventional CT criteria (73% vs 18%); in that study, neither positron emission tomography (PET) nor CT was associated with OS (PET, P = .833; CT, P = .557).83 Currently, predicting response to targeted therapy is driven largely by biopsy to assay the status of the mutation being targeted. Here, VEGFA is linked to non-small cell lung carcinoma.